Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $180,627.71 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,233 shares of Hims & Hers Health stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $55.87, for a total transaction of $180,627.71. Following the sale, the insider now owns 153,194 shares of the company’s stock, valued at approximately $8,558,948.78. This represents a 2.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, April 28th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.19, for a total transaction of $97,694.84.
• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92.
• On Monday, March 3rd, Soleil Boughton sold 4,151 shares of Hims & Hers Health stock. The shares were sold at an average price of $45.14, for a total transaction of $187,376.14.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72.

Hims & Hers Health Trading Up 8.3%

Shares of NYSE:HIMS opened at $56.74 on Friday. The company has a market capitalization of $12.70 billion, a PE ratio of 128.96 and a beta of 1.84. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The firm has a 50 day simple moving average of $39.85 and a 200-day simple moving average of $36.01.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.05 EPS. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently modified their holdings of the stock. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after purchasing an additional 8,364,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its position in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Nuveen LLC purchased a new stake in Hims & Hers Health in the 1st quarter valued at $58,403,000. Finally, Yong Rong HK Asset Management Ltd purchased a new stake in Hims & Hers Health in the 4th quarter valued at $41,104,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Needham & Company LLC restated a “buy” rating and issued a $61.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. UBS Group reiterated a “mixed” rating on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.